Superior Graft-versus-Leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 6, 2011, Pages 821-830

  Wang, Yu ^a   Liu, Dai Hong ^a   Xu, Lan Ping ^a   Liu, Kai Yan ^a   Chen, Huan ^a   Chen, Yu Hong ^a   Han, Wei ^a   Shi, Hong Xia ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Hematopoietic stem cell transplantation; HLA; Mismatched

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; HYDROXYUREA; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEMUSTINE; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD DONOR; CHILD; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HLA MATCHING; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RISK FACTOR; SIBLING;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHINA; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INCIDENCE; LEUKEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; SIBLINGS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING;

EID: 79956015814     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.08.023     Document Type: Article

References (35)

1. Ringden O., Zwaan F., Hermans J., Gratwohl A. European experience of bone marrow transplantation for leukemia. Transplant Proc 1987, 19:2600-2604.
2. Kanda Y., Chiba S., Hirai H., et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 2003, 102:1541-1547.
3. Szydlo R., Goldman J.M., Klein J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997, 15:1767-1777.
4. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985, 313:765-771.
5. Henslee-Downey P.J., Abhyankar S.H., Parrish R.S., et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997, 89:3864-3872.
6. Mehta J., Singhal S., Gee A.P., et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 2004, 33:389-396.
7. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractioned by soybean agglutinin and sheep red blood cells. Blood 1983, 61:341-348.
8. Aversa F., Tabilio A., Terenzi A., et al. Successful engraftment of T cell-depleted haploidentical " 3-loci" incompatibal transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994, 84:3948-3955.
9. Aversa F., Tabilio A., Velardi A., et al. Treatment high-risk acute leukemia with T-cell-depleted stem cells from related donors with on fully mismatched HLA haplotype. N Engl J Med 1998, 339:1186-1193.
10. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
11. Liu D., Tammik C., Zou J.Z., et al. Effect of combined T- and B-cell depletion of allogeniec HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients. Clin Transplant 2004, 18:518-524.
12. Aversa F., Reisner Y., Martelli M.F. The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008, 40:8-12.
13. Ciceri F., Labopin M., Aversa F., et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008, 112:3574-3581.
14. Huang X.J., Liu D.H., Liu K.Y., et al. Haplo-identical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.
15. Huang X.J., Liu D.H., Liu K.Y., et al. Treatment of acute leukaemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Bone Marrow Transplant 2009, 15:257-265.
16. Huang X.J., Xu L.P., Liu K.Y., et al. Partially matched related donor transplantation can achieve outcomes comparable to unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009, 15:4777-4783.
17. Gale R.P., Horowitz M.M., Weiner R.S., et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995, 16:203-208.
18. Huang X.J., Liu D.H., Liu K.Y., et al. Modified donor lymphocyte infusion after HLA-mismatched/haplo-identical T-cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008, 28:276-283.
19. Huang X.J., Liu D.H., Liu K.Y., Xu L.P., Chen H., Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haplo-identical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007, 92:414-417.
20. Huang X.J., Guo N.L., Ren H.Y., et al. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J 2003, 116:736-741.
21. Thomas E.D., Storb R., Clift R.A., et al. Bone marrow transplantation. N Engl J Med 1975, 292:895-902.
22. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
23. Scrucca L., Santucci A., Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010, E-pub ahead of print 11 January 2010; doi:. doi:10.1038/bmt.2009.359.
24. Beatty P.G., Anasetti C., Hansen J.A., et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for 1 HLA locus. Blood 1993, 81:249-253.
25. Ringdén O., Pavletic S.Z., Anasetti C., et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009, 113:3110-3118.
26. Drobyski W.R., Klein J., Flomenberg N., et al. Superior survival associated with transplantation of matched unrelated versus 1-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 2002, 99:806-814.
27. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
28. Burke M.J., Trotz B., Luo X., et al. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant 2009, 43:107-113.
29. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002, 30:681-686.
30. Basara N., Baurmann H., Kolbe K., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005, 35:1011-1018.
31. Remberger M., Storer B., Ringden O., Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002, 29:391-397.
32. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
33. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haplo-identical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
34. MacMillan M.L., DeFor T.E., Weisdorf D.J. The best endpoint for acute GVHD treatment trials. Blood 2010, 115:5412-5417.
35. Anasetti C., Beatty P.G., Storb R., et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990, 29:79-91.